Strata Critical Medical (SRTA) Gross Profit (2021 - 2026)

Strata Critical Medical (SRTA) has 6 years of Gross Profit data on file, last reported at $14.1 million in Q1 2026.

• Gross Profit for Q1 2026 came in at $14.1 million, up 100.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.8 million (up 113.84% YoY), and the FY2025 annual result was $41.1 million, up 38.99% from the prior year.
• Gross Profit improved to $14.1 million in Q1 2026 per SRTA's latest filing, from -$88.1 million in the prior quarter.
• Over five years, Gross Profit peaked at $69.2 million in Q2 2025 and troughed at -$127.6 million in Q4 2023.
• A 5-year average of -$3.8 million and a median of $10.4 million in 2023 frame the typical range for Gross Profit.
• The sharpest annual moves came in 2022 and 2025: Gross Profit surged 1582.25% in 2022, then sank 85.72% in 2025.
• A 5-year view of Gross Profit shows it stood at $5.1 million in 2022, then slumped by 2595.7% to -$127.6 million in 2023, then soared by 37.43% to -$79.8 million in 2024, then slipped by 10.42% to -$88.1 million in 2025, then soared by 116.02% to $14.1 million in 2026.
• Business Quant data shows SRTA's Gross Profit at $14.1 million in Q1 2026, -$88.1 million in Q4 2025, and $11.6 million in Q3 2025.